Tigermed is a contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.
Tigermed, founded in December, 2014 and headquartered in Hangzhou, is a contract research organization (CRO) focused on providing professional services for the entire process of clinical trials for new drug research. The founder is Ye Xiaoping. Listed on the SZSE on August 17, 2012, the company's major shareholders are Ye Xiaoping, Hong Kong Securities Clearing Co., Ltd and Cao Xiaochun. Rivals that have direct and indirect competition with Tigermed include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
The maximum payment limit of employee medical insurance in Shanghai in 2022 was raised to 590000 yuan
The private placement market is full of chaos, and the regulators' sword is intended to support the good and limit the bad
Cro plate fell, and Wuxi apptec fell nearly 10%
Tiger medicine: net profit in the first quarter increased by 13.82% year-on-year
2022 China AI Health 30 Report
ResearchConsumer Staples, Healthcare, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
The steel plate rose and Jinling mining rose by the limit
The leaders of Russia, France and Germany talked on the phone to discuss the situation in Ukraine
Baidu responded that it was unable to search "referee document network": caused by misoperation of the technical team
All Nippon Airways will cooperate with Joby, an enterprise invested by Toyota, on the flying car business, which is planned to be practical in 2025
CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
Baby concept stock change
Kuangda Technology: sign a 5.5 billion yuan filter chip R & D and production project
Kia's fourth quarter sales were 17.19 trillion won, lower than expected
WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell
According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index. It has been considered a top holding by many MSCI China indexes for some time.
Jun 08, 2020 09:51 AM
The pharmaceutical and biological sector has been heavily sold off by the main funds in the past three days
"Lingjing oasis" completed ten million yuan financing
Tiger medicine: after the share repurchase, the total transaction amount is about 500 million yuan
Cro stocks rose in early trading